Affiliation:
1. Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, MI 48109 , USA
2. School of Public Health, University of Michigan , Ann Arbor, MI 48109 , USA
3. Michigan State University College of Human Medicine , Grand Rapids, MI 49503 , USA
Abstract
Abstract
Context
Pheochromocytomas and paragangliomas (PPGL) are rare causes of secondary hypertension, but when unrecognized, they can lead to serious complications. Data regarding PPGL screening are lacking.
Objective
This study aimed to assess the rates and patterns of PPGL screening among eligible patients.
Methods
We conducted a retrospective review of adults with hypertension seen in outpatient clinics of a large academic center between January 1, 2017, and June 30, 2020. We included patients with treatment-resistant hypertension, hypertension at age < 35 years, and/or adrenal mass(es).
Results
Of 203 535 patients with hypertension identified, 71 088 (35%) met ≥ 1 inclusion criteria, and 2013 (2.83%) were screened for PPGL. Patients screened were younger (56.2 ± 17.4 vs 64.0 ± 17.1 years), more often women (54.1% vs 44.2%), and never-smokers (54.6% vs 47.5%, P < 0.001 for all). The rate of screening was highest in patients with hypertension and adrenal mass(es) (51.7%, vs 3.9% in patients with early-onset hypertension, and 2.4% in those with treatment-resistant hypertension). Multivariable logistic regression showed higher odds ratio (OR) of PPGL screening in women (OR [95% CI]: 1.48 [1.34-1.63]); Black vs White patients (1.35 [1.19-1.53]); patients with adrenal mass(es) (55.1 [44.53-68.15]), stroke (1.34 [1.16-1.54]), dyslipidemia (1.41 [1.26-1.58]), chronic kidney disease (1.40 [1.26-1.56]), and obstructive sleep apnea (1.96 [1.76-2.19]).
Conclusion
PPGL screening is pursued in roughly half of patients with adrenal nodules and hypertension, but rarely in patients with treatment-resistant or early-onset hypertension. Similar to screening for other forms of secondary hypertension, PPGL screening occurs more often after serious complications develop.
Funder
Doris Duke Charitable Foundation
National Heart, Lung, and Blood Institute
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference69 articles.
1. Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC/AHA hypertension guideline;Ritchey;J Clin Hypertens (Greenwich),2018
2. Prevalence of apparent treatment-resistant hypertension in the United States;Carey;Hypertension,2019
3. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients;Noubiap;Heart,2019
4. Deaths: final data for 2017;Kochanek;Natl Vital Stat Rep,2019
5. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003-2014;Kirkland;J Am Heart Assoc,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献